Risk-adapted first-line therapy selection in advanced EGFR-mutant NSCLC: a practical clinical algorithm integrating tumor biology and patient factors.
- DOI
- 10.1007/s12032-026-03338-y
- Published
- 2026 Aug 29
- Container
- Medical oncology (Northwood, London, England)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12032-026-03338-y,
title = {Risk-adapted first-line therapy selection in advanced EGFR-mutant NSCLC: a practical clinical algorithm integrating tumor biology and patient factors.},
author = {Sharma A and Tan JK and Kumar H and Bharadwaj HR},
year = {2026},
journal = {Medical oncology (Northwood, London, England)},
doi = {10.1007/s12032-026-03338-y},
url = {https://doi.org/10.1007/s12032-026-03338-y}
}RIS
TY - JOUR TI - Risk-adapted first-line therapy selection in advanced EGFR-mutant NSCLC: a practical clinical algorithm integrating tumor biology and patient factors. AU - Sharma A AU - Tan JK AU - Kumar H AU - Bharadwaj HR PY - 2026 JO - Medical oncology (Northwood, London, England) DO - 10.1007/s12032-026-03338-y UR - https://doi.org/10.1007/s12032-026-03338-y ER -
APA
A, S., JK, T., H, K., & HR, B. (2026). Risk-adapted first-line therapy selection in advanced EGFR-mutant NSCLC: a practical clinical algorithm integrating tumor biology and patient factors.. Medical oncology (Northwood, London, England). https://doi.org/10.1007/s12032-026-03338-y
Source records
- pubmed · retrieved 2026-09-27T14:02:21.468Z